Lemon Healthcare lists on the KOSDAQ market on July 6, while Remedy refunds subscription deposits on the same date ahead of its July 13 listing. HLgenomics continues demand forecasting through July 8 following an amended prospectus filed on July 2. Lemon Healthcare's retail subscription drew 1,510.57:1 competition with 3.7764 trillion won in deposits, and Remedy recorded 1,707:1 competition with 5.3 trillion won. HLgenomics detailed plans to invest 76.5 billion won in a second factory targeting groundbreaking in Q3 this year and commercial production in 2029. The second week of July sees active Korean IPO market participation across digital healthcare, portable X-ray equipment, and active pharmaceutical ingredient sectors.
Lemon Healthcare Lists on KOSDAQ with 1,510:1 Retail Subscription Competition
Lemon Healthcare lists on the KOSDAQ market on July 6. The company operates a medical MyData intermediary platform connecting hospitals and patients with medical records and healthcare data. Lemon Healthcare confirmed its IPO price at 10,000 won, the top of the proposed range. Institutional demand forecasting attracted 2,233 institutional investors with a competition ratio of 1,238:1. Approximately 99% of participating institutions proposed prices at or above the top of the range.
Retail subscription demand reached 755,284,210 shares for the 500,000-share retail allocation, producing a competition ratio of 1,510.57:1. Subscription deposits totaled 3.7764 trillion won. Among the 1.5 million shares allocated to institutional investors, lock-up commitments covered 1,112,575 shares (74.17% of institutional allocation): 296,514 shares with six-month lock-up, 91,938 shares with one-month lock-up, and 724,123 shares with 15-day lock-up. Non-committed shares totaled 387,425 shares (25.83%).
Remedy Refunds Subscription Deposits on July 6 Ahead of July 13 Listing
Remedy refunds retail subscription deposits on July 6 and lists on the KOSDAQ market on July 13. Retail subscription from July 1 recorded a competition ratio of 1,707:1. The 300,000-share retail allocation received 512 million shares in applications, with subscription deposits totaling 5.3 trillion won.
Remedy's institutional demand forecasting from July 17 to July 23 attracted 2,246 institutional investors with a competition ratio of 1,146:1. A total of 2,229 institutions proposed prices at or above the top of the range, confirming the IPO price at 20,700 won (the top of the 17,800–20,700 won range).
Remedy specializes in ultra-compact X-ray solutions. The company develops portable X-ray equipment designed for medical professionals to carry and operate directly. Its flagship product, the medical portable X-ray device 'KA6,' weighs 2.4 kg, reaches shooting readiness within five seconds of power-on, and captures 270 to 290 images per charge.
HLgenomics Continues Demand Forecasting After Filing Amended Prospectus on July 2
HLgenomics conducts demand forecasting through July 8. The company, a subsidiary of Hallym Pharmaceutical, produces active pharmaceutical ingredients (APIs) used by pharmaceutical companies to manufacture finished drugs such as tablets and injections. HLgenomics primarily manufactures APIs for chronic disease treatments in cardiovascular and respiratory categories.
The proposed IPO price range is 18,500–21,500 won. Total offering consists of 2,565,000 shares: 1,710,000 newly issued shares and 855,000 shares from existing shareholders (33.33% secondary offering). KB Securities serves as lead underwriter and IBK Investment & Securities as co-underwriter.
HLgenomics filed an amended prospectus on July 2 detailing second factory investment plans. The company states that production capacity at its first factory approaches limits and plans to allocate most IPO proceeds to facility investment. The amended filing specifies that second factory expansion requires total facility investment of 76.5 billion won. After deducting approximately 12.1 billion won already spent and approximately 31.7 billion won from IPO proceeds, the company plans to fund the remaining balance with cash reserves and future operating cash flow. The factory targets groundbreaking in Q3 this year, completion in Q4 next year, and commercial production start in 2029.
HLgenomics pursues second factory expansion not only for production capacity increase but also for overseas market entry to diversify customers and broaden medium- to long-term growth foundation. The company states it plans to design and construct the second factory to meet EU-GMP (European Union Good Manufacturing Practice) standards. This establishes infrastructure to supply APIs to global pharmaceutical companies and overseas finished drug manufacturers.
Meritz SPAC No. 2's 15-day lock-up shares are released this week. The volume subject to release is small. According to the securities issuance report, 15-day lock-up shares totaled 35,015 shares (0.7% of the 5.25 million-share institutional allocation). The remaining 5,214,985 shares were non-committed.
FAQ
What is Lemon Healthcare's IPO price and retail subscription competition ratio?
Lemon Healthcare's IPO price was confirmed at 10,000 won, the top of the proposed range. The retail subscription competition ratio reached 1,510.57:1, with subscription deposits totaling 3.7764 trillion won.
When does HLgenomics plan to complete its second factory and start commercial production?
HLgenomics targets groundbreaking for its second factory in Q3 this year, completion in Q4 next year, and commercial production start in 2029. The factory investment totals 76.5 billion won.
